Alliance for Clinical Trials in Oncology shared a post on X:
”Sara Tolaney leads Alliance for Clinical Trials in Oncology A012103 to compare the effect of pembrolizumab to observation in pts with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.”
Learn more here.
Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Alliance for Clinical Trials in Oncology on X, adding:
”We don’t know if TNBC patients who have pCR after Keynote 522 really benefit from 9 more cycles of pembro.
This trial will answer.”
More posts featuring Sarah Sammons.